XML 42 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
Sep. 30, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 33,067,421 $ 5,646,021
Short-term investments 13,104,863 8,034,001
Accounts receivable 10,574,199 830,433
Accounts receivable from affiliated entity 0 36,234
Prepaid expenses and other current assets 471,867 471,328
Prepaid expenses and other current assets from affiliated entity 573,017 887,167
Deferred tax asset 62,728 62,728
Total current assets 57,854,095 15,967,912
Restricted cash 100,674 100,410
Fixed assets, net 2,290,566 363,021
Investment in affiliated entity 11,084,123 10,703,332
Intangible assets, net 6,156,635 7,489,315
Goodwill 10,113,371 [1] 10,113,371 [1]
Common stock warrants 244,900 267,200
Other assets 171,000 134,193
Total assets 88,015,364 45,138,754
Current liabilities:    
Accounts payable and accrued expenses 4,020,494 3,181,574
Accounts payable and accrued expenses due to affiliated entity 494,460 187,275
Accrued clinical trial expenses 1,359,071 1,405,896
Common stock warrants 14,095,818 2,859,899
Deferred revenue 66,998 353,391
Deferred revenue from affiliated entity 401,041 388,542
Total current liabilities 20,437,882 8,376,577
Deferred revenue, net of current portion 1,724,547 88,609
Deferred revenue from affiliated entity, net of current portion 1,305,444 1,586,694
Deferred rent 2,166,849 65,076
Deferred tax liabilities 164,393 164,393
Total liabilities 25,799,115 10,281,349
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 207,620 144,313
Additional paid-in capital 341,979,766 263,897,116
Accumulated deficit (280,334,247) (229,760,129)
Accumulated other comprehensive (loss) income (98,022) 73,362
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 61,755,117 34,354,662
Non-controlling interest 461,132 502,743
Total stockholders' equity 62,216,249 34,857,405
Total liabilities and stockholders’ equity $ 88,015,364 $ 45,138,754
[1] Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.